8-K: CEL-SCI Corporation Raises $5 Million in Public Offering to Fuel Multikine Development

CEL-SCI Corporation announced the successful pricing and closing of a public offering of 2 million common shares at $2.50 each, generating $5 million in gross proceeds to advance its lead cancer immunotherapy, Multikine.

Summary

• CEL-SCI Corporation completed an underwritten public offering of 2,000,000 shares of its common stock.
• The shares were priced at $2.50 per share, resulting in total gross proceeds of $5,000,000.
• The underwriting discount was $0.175 per share, leading to net proceeds of $2.325 per share for the company before other offering expenses.
• The company granted the underwriters a 45-day option to purchase up to an additional 190,000 shares to cover over-allotments.
• The net proceeds from the offering are intended to fund the continued development of Multikine, for general corporate purposes, and working capital.
• Multikine, a clinical-stage cancer immunotherapy, holds Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
• The FDA has concurred with CEL-SCI's target patient selection criteria and has given approval to conduct a confirmatory Registration Study, which will enroll 212 newly diagnosed, locally advanced, primary treatment-naive, resectable head and neck cancer patients with no lymph node involvement and low PD-L1 tumor expression, a population estimated at 100,000 patients annually.

Sentiment

Score: 6

Explanation: The offering successfully secured capital for critical R&D, which is positive for a clinical-stage company. However, the capital raised is relatively small for a late-stage clinical program, and the offering results in shareholder dilution. The overall sentiment is cautiously positive due to the funding and regulatory progress for Multikine, balanced by the inherent risks of clinical development and the modest capital infusion.

Positives

• Successfully raised $5,000,000 in gross proceeds, providing essential capital for ongoing operations and product development.
• Funds are specifically earmarked for the continued development of Multikine, the company's key clinical-stage cancer immunotherapy asset.
• Multikine has received Orphan Drug designation from the FDA, which can provide significant development incentives and market exclusivity upon approval.
• The FDA's concurrence on target patient selection criteria for a confirmatory Registration Study is a crucial regulatory milestone, de-risking the clinical path forward.
• The identified target patient population for the confirmatory study (approximately 100,000 patients annually) indicates a substantial market opportunity for Multikine if it achieves regulatory approval.

Negatives

• The issuance of 2,000,000 new shares will result in dilution for existing shareholders.
• The underwriting discount of $0.175 per share (7% of the offering price) reduces the net capital received by the company from the gross proceeds.
• The company's ability to raise necessary capital is explicitly listed as a risk factor, suggesting potential ongoing capital needs beyond this offering.

Risks

• Inability to duplicate the clinical results demonstrated in previous studies for Multikine.
• Challenges in the timely development of any potential products that can be shown to be safe and effective.
• Difficulties in receiving necessary regulatory approvals from agencies like the FDA for Multikine or other potential products.
• Potential difficulties in manufacturing any of the company's potential products.
• Inability to raise necessary capital to fund ongoing operations and development activities.
• General risks and uncertainties faced by the company as detailed in its Annual Report on Form 10-K for the fiscal year ended September 30, 2024, and other SEC filings.

Future Outlook

The company intends to use the net proceeds from the offering to fund the continued development of Multikine, for general corporate purposes, and working capital. The FDA has concurred with CEL-SCI's target patient selection criteria for Multikine and has given the go-ahead to conduct a confirmatory Registration Study, which will enroll 212 newly diagnosed, locally advanced, primary treatment-naive, resectable head and neck cancer patients with no lymph node involvement and low PD-L1 tumor expression, representing about 100,000 patients annually.

Management Comments

• "CEL-SCI believes that boosting a patient's immune system before surgery, radiotherapy and chemotherapy have damaged it should provide the greatest possible impact on survival."
• "Multikine is designed to help the immune system 'target' the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor."

Industry Context

This capital raise by CEL-SCI Corporation is typical for a clinical-stage biotechnology company, especially one advancing a late-stage asset like Multikine. Companies in this sector frequently rely on equity financing to fund extensive and costly clinical trials, regulatory submissions, and pre-commercialization activities. The focus on cancer immunotherapy, particularly for head and neck cancer, aligns with a significant area of unmet medical need and ongoing research in the oncology space. The FDA's concurrence on patient selection for a confirmatory study positions Multikine as a potentially impactful therapy in a niche but substantial market segment, distinguishing it from earlier-stage competitors.

Comparison to Industry Standards

• The underwriting discount of 7% ($0.175 per share on a $2.50 offering price) is within the typical range for small-cap biotechnology public offerings, which often see discounts between 6% and 8% due to higher perceived risk and smaller deal sizes compared to larger, more established companies.
• The offering size of $5 million gross proceeds is relatively modest for a confirmatory Phase 3 study, suggesting that this capital raise might be a bridge financing or part of a larger, phased funding strategy. Larger Phase 3 trials, especially in oncology, often require tens to hundreds of millions of dollars.
• The grant of a 45-day over-allotment option for 190,000 shares (9.5% of the firm shares) is a standard practice in underwritten offerings, providing flexibility for underwriters to stabilize the stock price post-offering.
• The use of proceeds for 'continued development of Multikine, general corporate purposes, and working capital' is standard for a clinical-stage biotech, indicating ongoing operational needs and R&D investment.

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of new shares, but benefit from the company securing funding for its key drug development, potentially increasing long-term value if Multikine succeeds.
• Employees: Continued employment and stability due to secured funding for ongoing research and operations.
• Customers (future patients): Potential benefit from the continued development of Multikine, which aims to address a significant medical need in head and neck cancer.
• Creditors: Improved financial stability and liquidity for the company, potentially reducing credit risk.

Next Steps

• Continued development of Multikine.
• Conducting a confirmatory Registration Study for Multikine, enrolling 212 head and neck cancer patients.
• Maintaining listing of common stock on NYSE American.
• Filing all required reports with the SEC under the Exchange Act.

Key Dates

Recommendation

Keywords

CEL-SCI Corporation, CVM, Public Offering, Equity Raise, Common Stock, Multikine, Cancer Immunotherapy, Clinical Stage, Orphan Drug, FDA, Head and Neck Cancer, Oncology, Biotechnology, SEC Filing, ThinkEquity